CN111743998A - Composition for adjuvant therapy of enteritis and preparation method thereof - Google Patents

Composition for adjuvant therapy of enteritis and preparation method thereof Download PDF

Info

Publication number
CN111743998A
CN111743998A CN202010500357.1A CN202010500357A CN111743998A CN 111743998 A CN111743998 A CN 111743998A CN 202010500357 A CN202010500357 A CN 202010500357A CN 111743998 A CN111743998 A CN 111743998A
Authority
CN
China
Prior art keywords
parts
enteritis
composition
oligosaccharide
composite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010500357.1A
Other languages
Chinese (zh)
Inventor
张炜阳
年睿
贾儒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhongtong Meiya Life Health Shenzhen Co ltd
Original Assignee
Zhongtong Meiya Life Health Shenzhen Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhongtong Meiya Life Health Shenzhen Co ltd filed Critical Zhongtong Meiya Life Health Shenzhen Co ltd
Priority to CN202010500357.1A priority Critical patent/CN111743998A/en
Publication of CN111743998A publication Critical patent/CN111743998A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Abstract

The invention discloses a composition for adjuvant therapy of enteritis and a preparation method thereof, wherein the composition comprises the following raw materials in parts by mass: 2-6 parts of composite probiotic freeze-dried powder, 43-73 parts of composite prebiotics, 10-15 parts of sweetening agent, 1-2 parts of edible essence, 5-10 parts of wheat oligopeptide, 0.2-0.5 part of yeast extract and 10-20 parts of maltodextrin. The raw materials of the composition for adjuvant therapy of enteritis adopt the composite probiotic freeze-dried powder, the composite prebiotics, the wheat oligopeptide, the crystalline fructose, the yeast extract, the maltodextrin and the edible essence, and do not contain preservatives, and through the combined use of a plurality of probiotics, beneficial bacteria in gastrointestinal tracts are in an advantageous position, harmful bacteria are extruded through competitive occupation, the propagation of the harmful bacteria is inhibited, bacteriocin is secreted to kill the harmful bacteria, and the invasion of foreign pathogenic bacteria is prevented, so that the prepared solid beverage can play a role in adjuvant therapy of enteritis.

Description

Composition for adjuvant therapy of enteritis and preparation method thereof
Technical Field
The invention relates to the technical field of biological preparation, in particular to a composition for adjuvant therapy of enteritis and a preparation method thereof.
Background
Enteritis is caused by bacteria, viruses, fungi and parasites. The clinical manifestations mainly include abdominal pain, anorexia, abdominal distension, nausea and vomiting, and tenderness in the left lower abdomen, sometimes touching the spastic colon. Some patients may have fever and tenesmus, so they are also called infectious diarrhea. Enteritis is classified into acute and chronic types according to the length of the disease course.
The balance of intestinal flora plays an important role in constructing an intestinal mucosa barrier, maintaining normal immune function, resisting the invasion of pathogenic bacteria and the like, and the mechanism of the balance of intestinal flora comprises the generation of antibacterial substances, competitive adhesion with harmful bacteria, immunoregulation on a host and the like. Once the dynamic balance between the drug and the host and the external environment is broken, various diseases can be caused. In recent years, more and more researches show that the occurrence of enteritis is closely related to the imbalance of intestinal flora besides factors such as heredity, immunity, environment and the like.
The probiotics are active microorganisms, can be planted in intestinal tracts by oral administration, and play a role in regulating the number and the variety of intestinal flora, so that the ecological balance among the intestinal microorganisms is further restored. Generally, intestinal flora imbalance exists in enteritis patients, so that the use of probiotics to restore the intestinal microecological balance becomes a new means for treating enteritis, and certain curative effect is achieved in clinic. Prebiotics are used as a dietary supplement to beneficially affect the host by selectively stimulating the growth and activity of bacteria in one or more bacterial colonies, thereby improving the health of the host. Non-digestible food component, and has effects of promoting intestinal probiotic flora proliferation, improving and maintaining intestinal flora health, enhancing immunity, and preventing and treating enteritis.
Disclosure of Invention
Therefore, the invention provides a composition for adjuvant therapy of enteritis and a preparation method thereof.
In order to achieve the above purpose, the invention provides the following technical scheme:
the composition for adjuvant therapy of enteritis comprises the following raw materials in parts by mass: 2-6 parts of composite probiotic freeze-dried powder, 43-73 parts of composite prebiotics, 10-15 parts of sweetening agent, 1-2 parts of edible essence, 5-10 parts of wheat oligopeptide, 0.2-0.5 part of yeast extract and 10-20 parts of maltodextrin.
In one embodiment of the invention, the complex probiotics are selected from one or more of bifidobacterium lactis, bifidobacterium longum, bifidobacterium breve, lactobacillus rhamnosus, lactococcus lactis and streptococcus thermophilus.
In one embodiment of the invention, the number of the composite probiotic live bacteria contained in the composition for adjuvant therapy of enteritis is not less than 4.5 × 109CFU/g。
In one embodiment of the invention, the sweetener is selected from one or more of erythritol, xylitol, steviol glycosides and crystalline fructose.
In one embodiment of the invention, the complex prebiotics are selected from one or more of xylo-oligosaccharides, galacto-oligosaccharides, fructo-oligosaccharides and oat beta-glucan.
In one embodiment of the invention, the mass fractions of the components of the composite prebiotics are as follows: 10-15 parts of xylo-oligosaccharide, 15-25 parts of galacto-oligosaccharide, 15-25 parts of fructo-oligosaccharide and 3-8 parts of oat beta-glucan.
The invention also provides a method for preparing the composition for adjuvant therapy of enteritis, which is characterized by comprising the following steps:
taking the raw materials according to a certain proportion, mixing the composite prebiotics, the wheat oligopeptide, the yeast extract, the sweetener, the edible essence and the maltodextrin, and then sterilizing to obtain a first mixture;
and adding the composite probiotic freeze-dried powder into the first mixture and mixing to obtain the composition for adjuvant therapy of enteritis.
In one embodiment of the present invention, the sterilization process is:
irradiating the mixed raw materials under ultraviolet lamp with wavelength of 254nm for 15-30 min.
In one embodiment of the invention, the number of the composite probiotic live bacteria in the composition for adjuvant therapy of enteritis is not less than 4.5 × 109CFU/g。
In one embodiment of the invention, the complex prebiotics are selected from one or more of xylo-oligosaccharide, galacto-oligosaccharide, fructo-oligosaccharide and oat beta-glucan.
In the invention, the bifidobacterium breve is one of intestinal dominant bacteria of infants, and particularly has better relieving effect on infants with gastrointestinal dysfunction and patients with gastrointestinal dysfunction caused by long-term oral administration of antibiotics. The Bifidobacterium breve matched with Bifidobacterium longum or Bifidobacterium rett can rapidly help other probiotics colonize to promote intestinal flora to restore normal balance, and inhibit putrefying bacteria increase.
According to the invention, the lactobacillus rhamnosus is one of the most commonly researched strains in the world according to literature statistics, belongs to the lactobacillus casei (L.casei) category, and is updated into a single new strain after the identification technology is gradually improved. The application of the strain is quite wide, and the research and the report on maintaining the excellent bacterial phase of the intestinal tract, preventing and treating diarrhea, discharging toxin, improving the immunity, regulating excessive allergic symptoms, reducing the cholesterol of the body, preventing decayed teeth and the like are reported.
In the present invention, Bifidobacterium is mainly present in the large intestine, and can produce vitamin B group beneficial to human body and simultaneously reduce the incidence of severe diarrhea in infants. Research proves that the bacillus has the effects of resisting allergy, regulating intestines, improving constipation and the like, and can balance immune mechanisms, adjust the proportion of Th1/Th2 immune cells and produce in-vivo enzymes and vitamin B groups.
In the present invention, bifidobacteria are the main probiotic flora of the large intestine, and can produce vitamin B group in addition to reducing the incidence of severe diarrhea in infants. Research proves that the bifidobacterium lactis has the effects of resisting allergy, regulating intestines, improving constipation, balancing immune mechanism, regulating the proportion of Th1/Th2 immune cells, manufacturing in-vivo enzymes and vitamin B groups and the like.
In the present invention, lactococcus lactis is an indispensable bacterial species in milk-based fermented products, and belongs to lactobacillus sphaericus as the name suggests. More and more studies prove that the strain is helpful for improving human health, such as adjusting intestinal microenvironment, improving lactose discomfort and even exploring a plurality of other functions.
In the present invention, Streptococcus thermophilus is an indispensable bacterial species in milk-based fermented products, and belongs to Lactobacillus sphaericus as the name suggests. The streptococcus thermophilus is not only a RAS standard strain, but also is proved to be helpful for improving human health through more and more researches, such as adjusting intestinal microenvironment, regulating blood pressure, resisting cancer, improving lactose discomfort, even delaying senility and the like. In fermented foods, the fermentation uniqueness of streptococcus thermophilus is often adjusted by changing the ratio as a new food product is developed, so as to shorten the curd time, regulate acid production and increase viscosity.
The invention has the following advantages:
the raw materials of the composition for adjuvant therapy of enteritis adopt the composite probiotic freeze-dried powder, the composite prebiotics, the wheat oligopeptide, the crystalline fructose, the yeast extract, the maltodextrin and the edible essence, and do not contain preservatives, and through the combined use of a plurality of probiotics, beneficial bacteria in gastrointestinal tracts are in an advantageous position, harmful bacteria are extruded through competitive occupation, the propagation of the harmful bacteria is inhibited, bacteriocin is secreted to kill the harmful bacteria, and the invasion of foreign pathogenic bacteria is prevented, so that the prepared solid beverage can play a role in adjuvant therapy of enteritis.
The raw materials of the composition comprise various saccharides such as xylo-oligosaccharide, galacto-oligosaccharide, fructo-oligosaccharide, oat beta-glucan, crystalline fructose and the like, compared with sucrose, the composition has low calorific value and does not cause obesity, and various saccharides are combined for use, so that the hygroscopicity is reduced compared with single saccharide, and the prepared solid beverage is not easy to absorb moisture and harden.
The invention is prepared by a dry mixing process, ensures the viable count of probiotics, has simple operation and long shelf life, can be widely popularized, and the crystallized fructose has the function of increasing sweetness on one hand and is beneficial to the digestion and absorption of human bodies on the other hand.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below. It should be apparent that the drawings in the following description are merely exemplary, and that other embodiments can be derived from the drawings provided by those of ordinary skill in the art without inventive effort.
Fig. 1 is a flow chart of the preparation of the composition for adjuvant therapy of enteritis provided by the invention.
Detailed Description
The present invention is described in terms of particular embodiments, other advantages and features of the invention will become apparent to those skilled in the art from the following disclosure, and it is to be understood that the described embodiments are merely exemplary of the invention and that it is not intended to limit the invention to the particular embodiments disclosed. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
The invention provides a composition for adjuvant therapy of enteritis, which comprises the following raw materials in parts by mass: 0.5 part of bifidobacterium lactis freeze-dried powder, 0.5 part of bifidobacterium longum freeze-dried powder, 0.5 part of bifidobacterium breve freeze-dried powder, 0.5 part of lactobacillus rhamnosus freeze-dried powder, 0.5 part of lactococcus lactis freeze-dried powder, 0.5 part of streptococcus thermophilus freeze-dried powder, 10 parts of xylo-oligosaccharide, 15 parts of galacto-oligosaccharide, 15 parts of fructo-oligosaccharide, 3 parts of oat beta-glucan, 5 parts of wheat oligopeptide, 0.2 part of yeast extract, 10 parts of crystalline fructose, 10 parts of maltodextrin and 1 part of edible essence.
As shown in fig. 1, the preparation method of the composition for adjuvant therapy of enteritis in this embodiment is as follows:
taking the raw materials according to a certain proportion, adding the xylo-oligosaccharide, the galacto-oligosaccharide, the fructo-oligosaccharide, the oat beta-glucan, the wheat oligosaccharide, the yeast extract, the crystalline fructose, the maltodextrin and the edible essence into a stirrer, stirring and mixing, and then carrying out sterilization treatment to obtain a first mixture; wherein the sterilization treatment process comprises the following steps: irradiating the mixed raw materials under ultraviolet lamp with wavelength of 254nm for 15-30 min. Wherein the composite probiotic freeze-dried powder is bifidobacterium lactis freeze-dried powder, bifidobacterium longum freeze-dried powder, bifidobacterium breve freeze-dried powder, lactobacillus rhamnosus freeze-dried powder, lactococcus lactis freeze-dried powder and streptococcus thermophilus freeze-dried powder.
Adding the probiotics into the first mixture, mixing in a three-dimensional mixer, and keeping the stirring direction the same all the time during the mixing process to obtain the composition for adjuvant therapy of enteritis, wherein the number of composite probiotics living bacteria in the composition is not less than 4.5 × 109CFU/g。
And finally, mixing and bagging the obtained composition powder, wherein each bag is 4g, and storing the composition powder in a finished product warehouse which is cool, ventilated, dry, nontoxic, odorless and ratproof after being inspected to be qualified.
Example 2
The invention provides a composition for adjuvant therapy of enteritis, which comprises the following raw materials in parts by mass: 0.75 part of bifidobacterium lactis freeze-dried powder, 0.75 part of bifidobacterium longum freeze-dried powder, 0.75 part of bifidobacterium breve freeze-dried powder, 0.75 part of lactobacillus rhamnosus freeze-dried powder, 0.75 part of lactococcus lactis freeze-dried powder, 0.75 part of streptococcus thermophilus freeze-dried powder, 12.5 parts of xylo-oligosaccharide, 20 parts of galacto-oligosaccharide, 20 parts of fructo-oligosaccharide, 5.5 parts of oat beta-glucan, 7.5 parts of wheat oligopeptide, 0.35 part of yeast extract, 12.5 parts of crystalline fructose, 15 parts of maltodextrin and 1 part of edible essence.
And finally, mixing and bagging the obtained composition powder, wherein each bag is 4g, and storing and transporting after the inspection is qualified.
As shown in fig. 1, the preparation method of the composition for adjuvant therapy of enteritis in this embodiment is as follows:
taking the raw materials according to a certain proportion, mixing the xylo-oligosaccharide, the galacto-oligosaccharide, the fructo-oligosaccharide, the oat beta-glucan, the wheat oligosaccharide, the yeast extract, the crystalline fructose, the maltodextrin and the edible essence, and then sterilizing to obtain a first mixture; wherein the sterilization treatment process comprises the following steps: irradiating the mixed raw materials under ultraviolet lamp with wavelength of 254nm for 15-30 min. Wherein the composite probiotic freeze-dried powder is bifidobacterium lactis freeze-dried powder, bifidobacterium longum freeze-dried powder, bifidobacterium breve freeze-dried powder, lactobacillus rhamnosus freeze-dried powder, lactococcus lactis freeze-dried powder and streptococcus thermophilus freeze-dried powder.
The composition for adjuvant therapy of enteritis is obtained by adding the probiotic mixture into the first mixture, wherein the number of composite probiotic viable bacteria contained in the composition for adjuvant therapy of enteritis is not less than 4.5 × 109CFU/g。
Example 3
The invention provides a composition for adjuvant therapy of enteritis, which comprises the following raw materials in parts by mass: 1 part of bifidobacterium lactis freeze-dried powder, 1 part of bifidobacterium longum freeze-dried powder, 1 part of bifidobacterium breve freeze-dried powder, 1 part of lactobacillus rhamnosus freeze-dried powder, 1 part of lactococcus lactis freeze-dried powder, 1 part of streptococcus thermophilus freeze-dried powder, 15 parts of xylo-oligosaccharide, 25 parts of galacto-oligosaccharide, 25 parts of fructo-oligosaccharide, 8 parts of oat beta-glucan, 10 parts of wheat oligopeptide, 0.5 part of yeast extract, 15 parts of crystalline fructose, 20 parts of maltodextrin and 1 part of edible essence.
As shown in fig. 1, the preparation method of the composition for adjuvant therapy of enteritis in this embodiment is as follows:
taking the raw materials according to a certain proportion, mixing the xylo-oligosaccharide, the galacto-oligosaccharide, the fructo-oligosaccharide, the oat beta-glucan, the wheat oligopeptide, the yeast extract, the crystalline fructose, the maltodextrin and the edible essence, and then sterilizing to obtain a first mixture; wherein the sterilization treatment process comprises the following steps: irradiating the mixed raw materials under ultraviolet lamp with wavelength of 254nm for 15-30 min. Wherein the compound probiotic bacteria are Bifidobacterium lactis, Bifidobacterium longum, Bifidobacterium breve, Lactobacillus rhamnosus, lactococcus lactis, and Streptococcus thermophilus.
The composition for adjuvant therapy of enteritis is obtained by adding the probiotic mixture into the first mixture, wherein the number of composite probiotic viable bacteria contained in the composition for adjuvant therapy of enteritis is not less than 4.5 × 109CFU/g。
And finally, mixing and bagging the obtained composition powder, wherein each bag is 4g, and storing and transporting after the inspection is qualified.
Although the invention has been described in detail above with reference to a general description and specific examples, it will be apparent to one skilled in the art that modifications or improvements may be made thereto based on the invention. Accordingly, such modifications and improvements are intended to be within the scope of the invention as claimed.

Claims (10)

1. The composition for adjuvant therapy of enteritis is characterized by comprising the following raw materials in parts by mass: 2-6 parts of composite probiotic freeze-dried powder, 43-73 parts of composite prebiotics, 10-15 parts of sweetening agent, 1-2 parts of edible essence, 5-10 parts of wheat oligopeptide, 0.2-0.5 part of yeast extract and 10-20 parts of maltodextrin.
2. The composition for use in the adjuvant treatment of enteritis according to claim 1,
the composite probiotics are selected from one or more of bifidobacterium lactis, bifidobacterium longum, bifidobacterium breve, lactobacillus rhamnosus, lactococcus lactis and streptococcus thermophilus.
3. The composition for use in the adjuvant treatment of enteritis according to claim 1,
the number of composite probiotic viable bacteria contained in the composition for adjuvant therapy of enteritis is not less than 4.5 × 109CFU/g。
4. The composition for use in the adjuvant treatment of enteritis according to claim 1,
the sweetener is selected from one or more of erythritol, xylitol, stevioside and crystalline fructose.
5. The composition for use in the adjuvant treatment of enteritis according to claim 1,
the compound prebiotics are selected from one or more of xylo-oligosaccharide, galacto-oligosaccharide, fructo-oligosaccharide and oat beta-glucan.
6. The composition for use in the adjuvant treatment of enteritis according to claim 5,
the composite prebiotics comprise the following components in parts by weight: 10-15 parts of xylo-oligosaccharide, 15-25 parts of galacto-oligosaccharide, 15-25 parts of fructo-oligosaccharide and 3-8 parts of oat beta-glucan.
7. A method of preparing the composition of claim 1 for use in the adjuvant treatment of enteritis, comprising the steps of:
taking the raw materials according to a certain proportion, mixing the composite prebiotics, the wheat oligopeptide, the yeast extract, the sweetener, the edible essence and the maltodextrin, and then sterilizing to obtain a first mixture;
and adding the composite probiotic freeze-dried powder into the first mixture and mixing to obtain the composition for adjuvant therapy of enteritis.
8. The method of claim 7,
the sterilization treatment comprises the following steps:
irradiating the mixed raw materials under ultraviolet lamp with wavelength of 254nm for 15-30 min.
9. The method of claim 7,
the number of composite probiotic viable bacteria in the composition for adjuvant therapy of enteritis is not less than 4.5 × 109CFU/g。
10. The method of claim 7,
the compound prebiotics are selected from one or more of xylo-oligosaccharide, galacto-oligosaccharide, fructo-oligosaccharide and oat beta-glucan.
CN202010500357.1A 2020-06-04 2020-06-04 Composition for adjuvant therapy of enteritis and preparation method thereof Pending CN111743998A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010500357.1A CN111743998A (en) 2020-06-04 2020-06-04 Composition for adjuvant therapy of enteritis and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010500357.1A CN111743998A (en) 2020-06-04 2020-06-04 Composition for adjuvant therapy of enteritis and preparation method thereof

Publications (1)

Publication Number Publication Date
CN111743998A true CN111743998A (en) 2020-10-09

Family

ID=72674626

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010500357.1A Pending CN111743998A (en) 2020-06-04 2020-06-04 Composition for adjuvant therapy of enteritis and preparation method thereof

Country Status (1)

Country Link
CN (1) CN111743998A (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103476273A (en) * 2011-01-31 2013-12-25 纳图尔沃尔制药有限责任公司 Bifidobacterium bifidum strains for application in gastrointestinal diseases
CN105029407A (en) * 2015-04-14 2015-11-11 劲膳美生物科技股份有限公司 Medical formula food for inflammatory bowel disease
CN108135944A (en) * 2014-11-25 2018-06-08 伊夫罗生物科学公司 Probiotics and prebiotic compositions and its method and purposes for adjusting microorganism group
CN109222105A (en) * 2018-07-20 2019-01-18 徐谓 A kind of composite nutrient food and preparation method thereof that all-digestive tract improves
CN111000109A (en) * 2020-01-07 2020-04-14 中通美雅生命健康(深圳)有限公司 Synbiotic solid beverage for preventing and treating constipation and preparation method thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103476273A (en) * 2011-01-31 2013-12-25 纳图尔沃尔制药有限责任公司 Bifidobacterium bifidum strains for application in gastrointestinal diseases
CN108135944A (en) * 2014-11-25 2018-06-08 伊夫罗生物科学公司 Probiotics and prebiotic compositions and its method and purposes for adjusting microorganism group
CN105029407A (en) * 2015-04-14 2015-11-11 劲膳美生物科技股份有限公司 Medical formula food for inflammatory bowel disease
CN109222105A (en) * 2018-07-20 2019-01-18 徐谓 A kind of composite nutrient food and preparation method thereof that all-digestive tract improves
CN111000109A (en) * 2020-01-07 2020-04-14 中通美雅生命健康(深圳)有限公司 Synbiotic solid beverage for preventing and treating constipation and preparation method thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
国家食品药品监督管理总局等: "特殊医学用途配方食品 临床应用指南", 28 February 2015, 中国医药科技出版社, pages: 225 - 226 *

Similar Documents

Publication Publication Date Title
US7981412B2 (en) Food containing a probiotic and an isolated β-glucan and methods of use thereof
Chow Probiotics and prebiotics: a brief overview
RU2536939C2 (en) Compositions containing probiotic and prebiotic ingredients and inorganic salts with lactoferrin
US20100166721A1 (en) Probotic compositions and uses thereof
US20110165127A1 (en) Dairy-derived probiotic compositions and uses thereof
US20210228602A1 (en) Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants or young children born by c-section
KR20050057259A (en) Probiotic bacterium : lactobacillus fermentum
CN112056399A (en) Probiotic composition for enhancing immunity and application thereof
CN111528479A (en) Probiotics and prebiotics composition for relieving atopic dermatitis function and application
CN108850397A (en) A kind of probiotic gel candy and preparation method thereof of only diarrhea
CN111227261A (en) Prebiotic composition and application thereof
CN112075637A (en) Composition for reducing intestinal gas generation
CN114287633B (en) Probiotic composition containing cranberry and application thereof in helicobacter pylori resistance
CN112273657A (en) Probiotic composition for preventing or improving allergic diseases, preparation method and application
CN112741315A (en) Fruit probiotic dietary fiber powder solid beverage and preparation method thereof
CN111743998A (en) Composition for adjuvant therapy of enteritis and preparation method thereof
CN113057331A (en) Novel composite probiotic food
Gupta et al. Synbiotics: promoting gastrointestinal health
CN114568701B (en) Composition containing fructo-oligosaccharide and probiotics and application thereof
Surendran et al. Role of Synbiotics in Gastrointestinal Disorders
CN115299610B (en) Intestinal probiotics composition and application thereof
Ojima Priority effects in bifidobacterial communities: the importance of human milk oligosaccharides and arrival order in the infant gut microbiota assembly
CN116869106A (en) Probiotic solid beverage and preparation method thereof
CN114568699A (en) Composition containing galacto-oligosaccharides and probiotics and application thereof
RO137143A2 (en) Dietary supplement with pre- and pro-biotic role

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination